Filter by: patients
Home > Community Treatment Reports and Side Effects > Omnicef Treatment Report
What is Omnicef?

Omnicef® the brand name for cefdinir, a cephalosporin antibiotic. It is used to treat community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Lyme Disease 3 0
Other 2 1 Efficacy_none
UTI symptoms 1 0
Antibiotic 1 1 Efficacy_major
Increase effect of another treatment 1 0
Sinus infection chronic 1 0

See all 3 patients currently taking Omnicef

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 2
None
 2

Reported Dosages

  250 mg/5 mL daily 600 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Omnicef (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 6   Course of treatment ended: 86%
Did not seem to work 1   Did not seem to work: 14%
Doctor's advice 1   Doctor's advice: 14%

See all 7 patients who’ve stopped taking Omnicef

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking Omnicef

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Omnicef

Always
 4 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Omnicef

Very
 0 0%
Somewhat
 1 25%
A little
 0 0%
Not at all
 3 75%

Cost

Paid out of pocket

Cost of Omnicef

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 3 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 26, 2012.